It was a pleasure to meet with Yvette Raphael, patient advocate in HIV and Executive Director of Advocacy for Prevention of HIV and AIDS (APHA), South Africa, to share her perspective on evolving research, especially the use of bNAbs for preventing and treating HIV in women, young girls and at-risk populations. She also highlights the importance developing long acting antivirals and their access for women, young girls and at-risk populations from recent research presented at CROI 2023.
Broadly neutralizing antibodies (bNAbs) and long acting antivirals are a promising tool for preventing and treating HIV. Women and at-risk populations may benefit from bNAbs and long acting antivirals due to higher rates of HIV transmission. People living with HIV and those at risk are hopeful that advances will offer new options for protection and treatment, but more research is needed to understand their effectiveness and accessibility.
Interviews in this series:
Patient perspective: Landscape of HIV treatment and prevention in women and at-risk populations
Patient Perspective: Inclusivity of Women and underrepresented populations in HIV clinical trials
Patient Perspective: Disparities in HIV care and treatment
- How do you see the future of broadly neutralizing antibodies (bNAbs) affecting women at risk and living with HIV, and what important research was presented at CROI 2023? (0:16)
- Following research presented at CROI 2023, how do you see the landscape of HIV treatment and care evolving, and what role do you think your role and other patient advocates will play in shaping that evolution? (1:14)
Disclosures: Yvette Raphael has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Good afternoon and thanks for having me. My name is Yvette Raphael and I’m the Executive Director of Advocacy for the Prevention of HIV and AIDS (APHA) in South Africa.
How do you see the future of broadly neutralizing antibodies (bNAbs) affecting women at risk and living with HIV, and what important research was presented at CROI 2023? (0:16)
First of all, it’s important that we remember that research is always evolving. New things will always come up, and the future without being bNAbs is almost impossible, is going to be part of the future. It’s also important for us to remember that women and girls, and especially young people, have not had an opportunity to get any prevention method that works for them. Whatever the research may hold, as long as young women, and women don’t have access to what works for them specifically, it’s going to be difficult to work. I also want to say that it’s important for us to remember that research will forever, ever evolve.
Following research presented at CROI 2023, how do you see the landscape of HIV treatment and care evolving, and what role do you think your role and other patient advocates will play in shaping that evolution? (1:14)
Firstly, the research at CROI 2023 was very science based and it also gave us a glimpse of what the future is going to look like. I spoke a little bit about being bNAbs as well as cure and HIV, you know, whether it is of vaccines or not. Somehow the future is going to have to include long acting HIV prevention and treatment, where we have currently patients struggling with poor burdens. The future with long acting treatment and prevention looks like looks bright, and that’s what we are looking forward to.
Share this Video
Related Videos In HIV
Updated HIV primary care guidelines: Mamta Jain, ACTHIV 2023
Updated HIV primary care guidelines provide evidence-based and standardized approaches to manage individuals living with HIV, addressing their unique needs and challenges. By following these guidelines, healthcare providers can enhance patient outcomes and stay abreast of the latest research and treatment advancements in HIV care. In this interview, we speak with Dr Mamta Jain (UT […]
Managing liver complications and drug-drug interactions in HBV-HIV co-infection: ACTHIV 2023 with Jessie Torgersen
Liver complications and drug-drug interactions in HBV viremia in HIV patients are common, so it is important to consider complications and follow appropriate guidelines for patients when prescribing treatment. In this interview, we speak with Dr Jessie Torgersen (University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA) to explore considerations for healthcare professionals, including liver complications […]
HIV-HBV co-infection screening and monitoring guidelines: ACTHIV 2023, Jessie Torgersen
Screening and managing HIV-hepatitis B virus (HBV) co-infection is important due to increased risks in patients, therefore it is important to ensure standard practices involve comprehensive assessment, including serological testing and liver function evaluation, and healthcare professionals follow guidelines for regular monitoring to assess disease progression and treatment response. In this interview, we speak with […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!